Oruka Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Oruka Therapeutics, Inc. (ORKA) had Deferred Tax Assets, Operating Loss Carryforwards of $6.40 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $6.40M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $2.26M.
- 2013-12-31: Deferred Tax Assets, Operating Loss Carryforwards $39.80M.
- 2012-12-31: Deferred Tax Assets, Operating Loss Carryforwards $37.30M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $6.40M 10-K · filed 2026-03-12 |
| 2024-12-31 | $2.26M 10-K · filed 2026-03-12 |
| 2013-12-31 | $39.80M 10-K · filed 2014-03-20 |
| 2012-12-31 | $37.30M 10-K · filed 2014-03-20 |
| 2011-12-31 | $35.75M 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |